Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 06-Aug-2025.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Smallcap 250 and 1.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal Path Labs' Board, at its meeting on July 31, 2025, approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). The Board also declared an interim dividend of INR 6 per equity share (60% on face value of INR 10) for FY 2025-26, with the record date fixed as August 6, 2025; the dividend will be paid within 30 days. From the partially legible results, standalone profit after tax for Q1 FY26 came in around INR 1,293 million versus INR 1,484 million in the restated Q1 FY25, indicating a mid-teens year-on-year decline in earnings. Additionally, the Board amended the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) in line with SEBI insider trading norms.
Shareholders holding shares as of August 6, 2025 will be eligible for the INR 6 per share interim dividend, providing near-term cash return. The year-on-year dip in quarterly profit, partly distorted by the one-time deferred tax credit of INR 408 million in the prior-year base from the Suburban Diagnostics (SDIPL) liquidation, may draw investor attention but is unlikely to materially impact the stock given the company remains profitable and the dividend signals confidence in cash flows.